Dr. Robin M. Schaffran, MD

Dr. Schaffran practices at Laboratory Corporation of America in Agoura Hills, California.

Dr. Schaffran's NPI, 1790785822, was assigned on July 29, 2005. Dr. Schaffran graduated from University of Toronto Faculty of Medicine in 1995. Dr. Schaffran holds California license A68682.

Dr. Schaffran's primary practice is Laboratory Corporation of America, at 4301 Lost Hills Rd, Agoura Hills, CA 91301 in Los Angeles County. The practice phone is (858) 668-3700.

Dr. Schaffran's primary practice is Laboratory Corporation of America in Agoura Hills, California. Dmand AI also links Dr. Schaffran to 1 physician office, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schaffran practices. Vendor and product names are available with a free account.

Procedural dermatology is Dr. Schaffran's primary specialty in the NPI Registry, under taxonomy code 207NS0135X. Dr. Schaffran is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Schaffran's licenses on file in 2 states: California and Oregon.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, corns and calluses and facial skin infection among the conditions Dr. Schaffran treats.

CMS data shows 9,968 Medicare services from Dr. Schaffran across 23 procedure codes in 2024, for 1,207 Medicare patients. Medicare paid $440,744 for them. Every service was in an office.

CMS counts 1,207 Medicare patients who saw Dr. Schaffran in 2024. The largest group is 75 to 84, with 500 patients. 75% of them have high cholesterol, and 61% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.07, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Schaffran's median patient age at 69, with 58% women.

In 2024, Dr. Schaffran wrote 1,197 Medicare Part D claims for 512 patients. 93% of them were for generic drugs. CMS names the drug for 1,063 of them, across 21 drugs with 11 or more claims each, at $116,093 in total drug cost. In 2023, CMS named 875 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Schaffran for performance year 2024, reported individually. Dr. Schaffran accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Schaffran as offering telehealth. CMS counts 1,280 procedures of skin biopsy by Dr. Schaffran, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 2 papers to Dr. Schaffran.

CMS Open Payments shows 773 general payments to Dr. Schaffran from 48 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Sanofi and Genzyme US Companies paid the most, $1,595.

Dmand AI lists 1 award for Dr. Schaffran.

Dr. Schaffran graduated from University of Toronto Faculty of Medicine in 1995. Dr. Schaffran is a member of AAD.

Dr. Schaffran is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.